#blood cancer

UPDATE: On October 25, the FDA approved Tecvayli (teclistamab) to treat some people with multiple myeloma.

Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?

People with blood cancers or prostate cancer might be particularly vulnerable to COVID-19 complications.

African Americans between 18 and 39 with acute myeloid leukemia are more likely to die within five years compared with white people.

After treatment for multiple myeloma, Bryon Daily pays it forward to other African Americans, who are at higher risk for this cancer.

A new study clarifies the benefits and risks of treatments for those with multiple myeloma, a blood cancer more common in Black Americans.

People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.

98% of people who received the customized immunotherapy responded to the one-time treatment.

The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.

Studies evaluate the impact of COVID-19 infection, treatments and vaccination in this uniquely vulnerable population.

Studies point to strategies to reduce disparities, improve outcomes and support shared decision-making.

Screening high-risk groups could improve the survival of patients who develop myeloma.

Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.